Anzeige
Mehr »
Login
Freitag, 11.10.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Die Multimilliarden-Dollar-Fonds, die auf NexGold Mining setzen - Was wissen sie?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 870481 | ISIN: FR0000032526 | Ticker-Symbol: 4G8
Frankfurt
11.10.24
08:01 Uhr
35,300 Euro
+0,150
+0,43 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
GUERBET SA Chart 1 Jahr
5-Tage-Chart
GUERBET SA 5-Tage-Chart
RealtimeGeldBriefZeit
35,70036,50022:58
Dow Jones News
461 Leser
Artikel bewerten:
(2)

Guerbet strengthens its Executive Committee with two new appointments to consolidate its medium and long-term ambitions.

DJ Guerbet strengthens its Executive Committee with two new appointments to consolidate its medium and long-term ambitions.

Guerbet 
Guerbet strengthens its Executive Committee with two new appointments to consolidate its medium and long-term 
ambitions. 
11-March-2024 / 08:00 CET/CEST 
Dissemination of a French Regulatory News, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Guerbet strengthens its Executive Committee    with two new appointments to consolidate         its medium 
and long-term ambitions 
 . Christine Allard, SVP Public Affairs and Corporate Communications 
 . Eva Ohlsson, SVP Human Resources 
Villepinte, 11 march 2024: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical 
imaging, announces the strengthening of its management team with two appointments. Christine Allard and Eva Ohlsson 
have joined the Group as senior Vice-President Public Affairs and Corporate Communications, and Senior Vice President 
Human Resources respectively. Reporting directly to David Hale, Chief Executive Officer, they will both become members 
of Guerbet's Executive Committee. 
Christine Allard brings over 25 years of experience across sales, marketing, communications, corporate social 
responsibility, and public affairs. She has held a variety of different roles at both the regional and group level at 
BSN-Danone, Pechiney-Alcan, and most recently with the group Sanef-Abertis where she was Director of Communications and 
Public Affairs. Christine Allard will leverage her expertise in corportae and digital communications, corporate social 
responsibility programs as well as her established relationships with key government institutions to contribute to 
Guerbet's strategic development. She is also President of the Chamber of Commerce of Spain in France (COCEF) and 
received the distinction of "Chevalier dans l'Ordre de la Légion d'Honneur" in 2009. 
 
 
Eva Ohlsson brings over 20 years of human resources (HR) experience with specific expertise in recruiting, developing 
and managing talent in the healthcare sector. She has held a variety of different HR roles at both the regional and 
global level, has been HR business partner for commercial, R&D and Product Development organizations. During the past 
five years, Eva Ohlsson was the Group HR Director for Stago, a global player in the In-Vitro Diagnosis (IVD) industry, 
wholly dedicated to the exploration of hemostasis and thrombosis. She played a full part in the development of this 
french based family-owned healthcare group, which is characterised both by numerous sales affiliates around the world 
and a large industrial network split between France, United States and China. Eva was also in charge of co-leading the 
Corporate Sustainability Initiative for Stago. 
 
 Guerbet's Executive Committee now has 10 members: . David Hale, Chief Executive Officer . Christine Allard, SVP Public Affairs and Corporate Communications . Charlotte Bamière, General Counsel & SVP Compliance . Raoul Bernhardt, SVP Industrial Operations, EHS and Procurement . Philippe Bourrinet, SVP Development, Medical & Regulatory Affairs and Group Responsible Pharmacist . Valérie Brissart, SVP Marketing - Diagnostic Imaging . Jérôme Estampes, Chief Financial Officer and SVP IT and Business Development & Licensing . François Nicolas, SVP Research, Development, Innovation and AI . Eva Ohlsson, SVP Human Resources . Dan Raffi, SVP Commercial Operations Upcoming event: Publication of 2023 annual revenue 20 march 2024 after trading About Guerbet At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a world leader in medical imaging, offering a complete range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. Pioneers in contrast media for 95 years, with more than 2,830 employees worldwide, we are constantly innovating and devote 8% to 10% of our revenue to research and development in five centres in France, Israel, and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B-mid caps) and generated EUR753 million in revenue in 2022. For more information, please visit www.guerbet.com. Contacts: Guerbet Jérôme Estampes, Chief Financial Officer +33.1.45.91.50.00 / jerome.estampes@guerbet.com Christine Allard, Public Affairs and Corporate Communications Director +33.6.30.11.57.82 / christine.allard@guerbet.com Seitosei.Actifin Marianne Py, Financial Communications + 33.1.56.88.11.25 / mpy@actifin.fr Jennifer Jullia, Press +33.1.56.88.11.19 / jjullia@actifin.fr 

-----------------------------------------------------------------------------------------------------------------------

Regulatory filing PDF file File: GUERBET_nominations_11032024ukVdef

=------------------------------------------------------- 
Language:    English 
Company:     Guerbet 
         Zone Paris Nord II 15 Rue des Vanesses 
         93420 Villepinte 
         France 
Internet:    https://www.guerbet.com/investors 
ISIN:      FR0000032526 
Euronext Ticker: GBT 
AMF Category:  Inside information / Other releases 
EQS News ID:   1855041 
 
End of Announcement EQS News Service 
=------------------------------------------------------------------------------------ 

1855041 11-March-2024 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1855041&application_name=news

(END) Dow Jones Newswires

March 11, 2024 03:00 ET (07:00 GMT)

© 2024 Dow Jones News
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.